Search

Your search keyword '"Poggio, Francesca"' showing total 327 results
Start Over Author "Poggio, Francesca"
327 results on '"Poggio, Francesca"'

1. Patterns of care at the end of life: a retrospective study of Italian patients with advanced breast cancer

Author

Giannubilo, Irene, Battistuzzi, Linda, Blondeaux, Eva, Ruelle, Tommaso, Poggio, Francesca Benedetta, Buzzatti, Giulia, D’Alonzo, Alessia, Della Rovere, Federica, Latocca, Maria Maddalena, Molinelli, Chiara, Razeti, Maria Grazia, Nardin, Simone, Arecco, Luca, Perachino, Marta, Favero, Diletta, Borea, Roberto, Pronzato, Paolo, Del Mastro, Lucia, and Bighin, Claudia

Published
2024
Full Text
View/download PDF

2. Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium

Author

Brandão, Mariana, Martins-Branco, Diogo, De Angelis, Claudia, Vuylsteke, Peter, Gelber, Richard D., Van Damme, Nancy, van Walle, Lien, Ferreira, Arlindo R., Lambertini, Matteo, Poggio, Francesca, Verhoeven, Didier, Barbeaux, Annelore, Duhoux, Francois P., Wildiers, Hans, Caballero, Carmela, Awada, Ahmad, Piccart-Gebhart, Martine, Punie, Kevin, and de Azambuja, Evandro

Published
2024
Full Text
View/download PDF

3. Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium

Author

Brandão, Mariana, Martins-Branco, Diogo, De Angelis, Claudia, Vuylsteke, Peter, Gelber, Richard D., Van Damme, Nancy, van Walle, Lien, Ferreira, Arlindo R., Lambertini, Matteo, Poggio, Francesca, Verhoeven, Didier, Barbeaux, Annelore, Duhoux, Francois P., Wildiers, Hans, Caballero, Carmela, Awada, Ahmad, Piccart-Gebhart, Martine, Punie, Kevin, and de Azambuja, Evandro

Published
2024
Full Text
View/download PDF

4. Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study

Author

Arecco, Luca, Latocca, Maria Maddalena, Blondeaux, Eva, Riccardi, Ferdinando, Mocerino, Carmela, Guarneri, Valentina, Mioranza, Eleonora, Bisagni, Giancarlo, Gasparini, Elisa, Puglisi, Fabio, Membrino, Alexandro, Ferro, Antonella, Adamo, Vincenzo, Giovanardi, Filippo, Tamberi, Stefano, Donati, Sara, Landucci, Elisabetta, Biganzoli, Laura, Piccinini, Sara, Pastorino, Simona, de Azambuja, Evandro, Poggio, Francesca, Lambertini, Matteo, and Del Mastro, Lucia

Published
2024
Full Text
View/download PDF

6. The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancer

Author

Rebaudi, Federico, De Franco, Fabiana, Goda, Rayan, Obino, Valentina, Vita, Giorgio, Baronti, Camilla, Iannone, Eleonora, Pitto, Francesca, Massa, Barbara, Fenoglio, Daniela, Jandus, Camilla, Poggio, Francesca, Fregatti, Piero, Melaiu, Ombretta, Bozzo, Matteo, Candiani, Simona, Papaccio, Federica, Greppi, Marco, Pesce, Silvia, and Marcenaro, Emanuela

Published
2024
Full Text
View/download PDF

7. Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

Author

Lambertini, Matteo, Blondeaux, Eva, Bisagni, Giancarlo, Mura, Silvia, De Placido, Sabino, De Laurentiis, Michelino, Fabi, Alessandra, Rimanti, Anita, Michelotti, Andrea, Mansutti, Mauro, Russo, Antonio, Montemurro, Filippo, Frassoldati, Antonio, Durando, Antonio, Gori, Stefania, Turletti, Anna, Tamberi, Stefano, Urracci, Ylenia, Fregatti, Piero, Razeti, Maria Grazia, Caputo, Roberta, De Angelis, Carmine, Sanna, Valeria, Gasparini, Elisa, Agostinetto, Elisa, de Azambuja, Evandro, Poggio, Francesca, Boni, Luca, and Del Mastro, Lucia

Published
2023
Full Text
View/download PDF

8. Dose-dense adjuvant chemotherapy in patients with HER2-low early breast cancer: An exploratory analysis of the GIM2 trial.

Author

Molinelli, Chiara, primary, Delucchi, Virginia, additional, Blondeaux, Eva, additional, Boni, Luca, additional, Poggio, Francesca, additional, Arpino, Grazia, additional, Nisticò, Cecilia, additional, Fabi, Alessandra, additional, De Laurentiis, Michelino, additional, Puglisi, Fabio, additional, Nader Marta, Guilherme, additional, Fozza, Alessandra, additional, Pitto, Francesca, additional, Lambertini, Matteo, additional, and Del Mastro, Lucia, additional

Published
2024
Full Text
View/download PDF

9. Impact of young age at diagnosis on survival outcomes in patients with early breast cancer according to tumor subtype: Pooled analysis of 5 randomized clinical trials from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM).

Author

Perachino, Marta, primary, Blondeaux, Eva, additional, De Laurentiis, Michelino, additional, Arpino, Grazia, additional, Puglisi, Fabio, additional, Fabi, Alessandra, additional, Gori, Stefania, additional, Poggio, Francesca, additional, Arecco, Luca, additional, Favero, Diletta, additional, Sydes, Matthew R., additional, Lambertini, Matteo, additional, and Del Mastro, Lucia, additional

Published
2024
Full Text
View/download PDF

10. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial

Author

Venturini, M, Abate, A, Pastorino, S, Canavese, G, Vecchio, C, Guenzi, M, Lambertini, M, Levaggi, A, Giraudi, S, Accortanzo, V, Floris, C.A., Aitini, E, Fornari, G, Miraglia, S, Buonfanti, G, Cherchi, M.C., Petrelli, F, Vaccaro, A, Magnolfi, E, Contu, A, Labianca, R, Parisi, A, Basurto, C, Cappuzzo, F, Merlano, M, Russo, S, Mansutti, M, Poletto, E, Nardi, M, Grasso, D, Fontana, A, Isa, L, Comandè, M, Cavanna, L, Iacobelli, S, Milani, S, Mustacchi, G, Venturini, S, Scinto, A.F., Sarobba, M.G., Pugliese, P, Bernardo, A, Pavese, I, Coccaro, M, Massidda, B, Ionta, M.T., Nuzzo, A, Laudadio, L, Chiantera, V, Dottori, R, Barduagni, M, Castiglione, F, Ciardiello, F, Tinessa, V, Ficorella, A, Moscetti, L, Vallini, I, Giardina, G, Silva, R, Montedoro, M, Seles, E, Morano, F, Cruciani, G, Adamo, V, Pancotti, A, Palmisani, V, Ruggeri, A, Cammilluzzi, E, Carrozza, F, D'Aprile, M, Brunetti, M, Gallotti, P, Chiesa, E, Testore, F, D'Arco, A, Ferro, A, Jirillo, A, Pezzoli, M, Scambia, G, Iacono, C, Masullo, P, Tomasello, G, Gandini, G, Zoboli, A, Bottero, C, Cazzaniga, M, Genua, G, Palazzo, S, D'Amico, M, Perrone, D, Del Mastro, Lucia, Poggio, Francesca, Blondeaux, Eva, De Placido, Sabino, Giuliano, Mario, Forestieri, Valeria, De Laurentiis, Michelino, Gravina, Adriano, Bisagni, Giancarlo, Rimanti, Anita, Turletti, Anna, Nisticò, Cecilia, Vaccaro, Angela, Cognetti, Francesco, Fabi, Alessandra, Gasparro, Simona, Garrone, Ornella, Alicicco, Maria Grazia, Urracci, Ylenia, Mansutti, Mauro, Poletti, Paola, Correale, Pierpaolo, Bighin, Claudia, Puglisi, Fabio, Montemurro, Filippo, Colantuoni, Giuseppe, Lambertini, Matteo, and Boni, Luca

Published
2022
Full Text
View/download PDF

12. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient–Level Data

Author

Lambertini, Matteo, Moore, Halle CF, Leonard, Robert CF, Loibl, Sibylle, Munster, Pamela, Bruzzone, Marco, Boni, Luca, Unger, Joseph M, Anderson, Richard A, Mehta, Keyur, Minton, Susan, Poggio, Francesca, Albain, Kathy S, Adamson, Douglas JA, Gerber, Bernd, Cripps, Amy, Bertelli, Gianfilippo, Seiler, Sabine, Ceppi, Marcello, Partridge, Ann H, and Del Mastro, Lucia

Subjects
Breast Cancer, Clinical Trials and Supportive Activities, Contraception/Reproduction, Cancer, Clinical Research, Aging, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adult, Breast Neoplasms, Disease-Free Survival, Female, Fertility Preservation, Gonadotropin-Releasing Hormone, Humans, Organ Sparing Treatments, Ovary, Premenopause, Primary Ovarian Insufficiency, Randomized Controlled Trials as Topic, Treatment Outcome, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose The role of temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal women remains controversial. This systematic review and meta-analysis using individual patient-level data was conducted to better assess the efficacy and safety of this strategy in patients with early breast cancer. Methods The trials in which premenopausal women with early breast cancer were randomly assigned to receive (neo)adjuvant chemotherapy alone or with concurrent GnRHa were eligible for inclusion. Primary end points were premature ovarian insufficiency (POI) rate and post-treatment pregnancy rate. Disease-free survival and overall survival were secondary end points. Because each study represents a cluster, statistical analyses were performed using a random effects model. Results A total of 873 patients from five trials were included. POI rate was 14.1% in the GnRHa group and 30.9% in the control group (adjusted odds ratio, 0.38; 95% CI, 0.26 to 0.57; P < .001). A total of 37 (10.3%) patients had at least one post-treatment pregnancy in the GnRHa group and 20 (5.5%) in the control group (incidence rate ratio, 1.83; 95% CI, 1.06 to 3.15; P = .030). No significant differences in disease-free survival (adjusted hazard ratio, 1.01; 95% CI, 0.72 to 1.42; P = .999) and overall survival (adjusted hazard ratio, 0.67; 95% CI, 0.42 to 1.06; P = .083) were observed between groups. Conclusion Our findings provide evidence for the efficacy and safety of temporary ovarian suppression with GnRHa during chemotherapy as an available option to reduce the likelihood of chemotherapy-induced POI and potentially improve future fertility in premenopausal patients with early breast cancer.

Published
2018

13. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial

Author

Del Mastro, Lucia, Mansutti, Mauro, Bisagni, Giancarlo, Ponzone, Riccardo, Durando, Antonio, Amaducci, Laura, Campadelli, Enrico, Cognetti, Francesco, Frassoldati, Antonio, Michelotti, Andrea, Mura, Silvia, Urracci, Ylenia, Sanna, Giovanni, Gori, Stefania, De Placido, Sabino, Garrone, Ornella, Fabi, Alessandra, Barone, Carla, Tamberi, Stefano, Bighin, Claudia, Puglisi, Fabio, Moretti, Gabriella, Arpino, Grazia, Ballestrero, Alberto, Poggio, Francesca, Lambertini, Matteo, Montemurro, Filippo, and Bruzzi, Paolo

Published
2021
Full Text
View/download PDF

17. Multidisciplinary and Tailored Treatment of Locally Advanced Breast Cancer in Progression during Neoadjuvant Chemotherapy: Case Report.

Author

Cuniolo, Letizia, Gipponi, Marco, Murelli, Federica, Depaoli, Francesca, Cornacchia, Chiara, Franchelli, Simonetta, Pesce, Marianna, Ronda, Elena, Picardi, Stefano, Diaz, Raquel, Poggio, Francesca, Friedman, Daniele, De Cian, Franco, and Fregatti, Piero

Subjects
METASTATIC breast cancer, NEOADJUVANT chemotherapy, CANCER invasiveness, LITERATURE reviews, DISEASE progression
Abstract

Locally advanced breast cancer (LABC) is a complex disease that requires a multidisciplinary approach. Neoadjuvant chemotherapy (NAC) is usually performed in order to achieve loco-regional radical resection; although its importance in the multidisciplinary approach to LABC is well recognized, a small number of patients show Progressive Disease (PD). No standard salvage treatment (ST) has been defined and different strategies can be adopted, such as second-line systemic therapies, radiation therapy, and surgery. Herein, a case of LABC in PD during NAC is reported with a literature review, with the aim of highlighting the importance of a tailored multidisciplinary treatment for each patient. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study

Author

Conte, Benedetta, Fabi, Alessandra, Poggio, Francesca, Blondeaux, Eva, Dellepiane, Chiara, D’Alonzo, Alessia, Buono, Giuseppe, Arpino, Grazia, Magri, Valentina, Naso, Giuseppe, Presti, Daniele, Mura, Silvia, Fontana, Andrea, Cognetti, Francesco, Molinelli, Chiara, Pastorino, Simona, Bighin, Claudia, Miglietta, Loredana, Boccardo, Francesco, Lambertini, Matteo, and Del Mastro, Lucia

Published
2020
Full Text
View/download PDF

19. Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial

Author

Lambertini, Matteo, Agbor-Tarh, Dominique, Metzger-Filho, Otto, Ponde, Noam F., Poggio, Francesca, Hilbers, Florentine S., Korde, Larissa A., Chumsri, Saranya, Werner, Olena, Del Mastro, Lucia, Caparica, Rafael, Moebus, Volker, Moreno-Aspitia, Alvaro, Piccart, Martine J., and de Azambuja, Evandro

Published
2020
Full Text
View/download PDF

20. Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study

Author

Blondeaux, Eva, Ferreira, Arlindo R., Poggio, Francesca, Puglisi, Fabio, Bighin, Claudia, Sottotetti, Federico, Montemurro, Filippo, Poletto, Elena, Lai, Antonella, Sini, Valentina, Minuti, Gabriele, Mura, Silvia, Fontana, Andrea, Fregatti, Piero, Cardinali, Barbara, Lambertini, Matteo, and Del Mastro, Lucia

Published
2020
Full Text
View/download PDF

22. Supplementary Table S12 from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials

Author

Conte, Benedetta, primary, Boni, Luca, primary, Bisagni, Giancarlo, primary, Durando, Antonio, primary, Sanna, Giovanni, primary, Gori, Stefania, primary, Garrone, Ornella, primary, Tamberi, Stefano, primary, De Placido, Sabino, primary, Schettini, Francesco, primary, Pazzola, Antonio, primary, Ponzone, Riccardo, primary, Montemurro, Filippo, primary, Lunardi, Gianluigi, primary, Notaro, Rosario, primary, De Angioletti, Maria, primary, Turletti, Anna, primary, Mansutti, Mauro, primary, Puglisi, Fabio, primary, Frassoldati, Antonio, primary, Porpiglia, Mauro, primary, Fabi, Alessandra, primary, Generali, Daniele, primary, Scognamiglio, Giovanni, primary, Rossi, Maura, primary, Brasó-Maristany, Fara, primary, Prat, Aleix, primary, Cardinali, Barbara, primary, Piccioli, Patrizia, primary, Serra, Martina, primary, Lastraioli, Sonia, primary, Bighin, Claudia, primary, Poggio, Francesca, primary, Lambertini, Matteo, primary, and Del Mastro, Lucia, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure S1 from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials

Author

Conte, Benedetta, primary, Boni, Luca, primary, Bisagni, Giancarlo, primary, Durando, Antonio, primary, Sanna, Giovanni, primary, Gori, Stefania, primary, Garrone, Ornella, primary, Tamberi, Stefano, primary, De Placido, Sabino, primary, Schettini, Francesco, primary, Pazzola, Antonio, primary, Ponzone, Riccardo, primary, Montemurro, Filippo, primary, Lunardi, Gianluigi, primary, Notaro, Rosario, primary, De Angioletti, Maria, primary, Turletti, Anna, primary, Mansutti, Mauro, primary, Puglisi, Fabio, primary, Frassoldati, Antonio, primary, Porpiglia, Mauro, primary, Fabi, Alessandra, primary, Generali, Daniele, primary, Scognamiglio, Giovanni, primary, Rossi, Maura, primary, Brasó-Maristany, Fara, primary, Prat, Aleix, primary, Cardinali, Barbara, primary, Piccioli, Patrizia, primary, Serra, Martina, primary, Lastraioli, Sonia, primary, Bighin, Claudia, primary, Poggio, Francesca, primary, Lambertini, Matteo, primary, and Del Mastro, Lucia, primary

Published
2023
Full Text
View/download PDF

24. Data from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials

Author

Conte, Benedetta, primary, Boni, Luca, primary, Bisagni, Giancarlo, primary, Durando, Antonio, primary, Sanna, Giovanni, primary, Gori, Stefania, primary, Garrone, Ornella, primary, Tamberi, Stefano, primary, De Placido, Sabino, primary, Schettini, Francesco, primary, Pazzola, Antonio, primary, Ponzone, Riccardo, primary, Montemurro, Filippo, primary, Lunardi, Gianluigi, primary, Notaro, Rosario, primary, De Angioletti, Maria, primary, Turletti, Anna, primary, Mansutti, Mauro, primary, Puglisi, Fabio, primary, Frassoldati, Antonio, primary, Porpiglia, Mauro, primary, Fabi, Alessandra, primary, Generali, Daniele, primary, Scognamiglio, Giovanni, primary, Rossi, Maura, primary, Brasó-Maristany, Fara, primary, Prat, Aleix, primary, Cardinali, Barbara, primary, Piccioli, Patrizia, primary, Serra, Martina, primary, Lastraioli, Sonia, primary, Bighin, Claudia, primary, Poggio, Francesca, primary, Lambertini, Matteo, primary, and Del Mastro, Lucia, primary

Published
2023
Full Text
View/download PDF

25. Choosing the appropriate pharmacotherapy for breast cancer during pregnancy: what needs to be considered?

Author

Favero, Diletta, primary, Lapuchesky, Laura Sabina, additional, Poggio, Francesca, additional, Nardin, Simone, additional, Perachino, Marta, additional, Arecco, Luca, additional, Scavone, Graziana, additional, Ottonello, Silvia, additional, Latocca, Maria Maddalena, additional, Borea, Roberto, additional, Puglisi, Silvia, additional, Cosso, Maurizio, additional, Fozza, Alessandra, additional, Spinaci, Stefano, additional, and Lambertini, Matteo, additional

Published
2023
Full Text
View/download PDF

26. Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study

Author

Blondeaux, Eva, Lambertini, Matteo, Michelotti, Andrea, Conte, Benedetta, Benasso, Marco, Dellepiane, Chiara, Bighin, Claudia, Pastorino, Simona, Levaggi, Alessia, Alonzo, Alessia D’, Poggio, Francesca, Buzzatti, Giulia, Molinelli, Chiara, Fregatti, Piero, Bertoglio, Sergio, Boccardo, Francesco, and Del Mastro, Lucia

Published
2020
Full Text
View/download PDF

28. Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium

Author

Brandão, Mariana, primary, Martins-Branco, Diogo, additional, De Angelis, Claudia, additional, Vuylsteke, Peter, additional, Gelber, Richard D., additional, Van Damme, Nancy, additional, van Walle, Lien, additional, Ferreira, Arlindo R., additional, Lambertini, Matteo, additional, Poggio, Francesca, additional, Verhoeven, Didier, additional, Barbeaux, Annelore, additional, Duhoux, Francois P., additional, Wildiers, Hans, additional, Caballero, Carmela, additional, Awada, Ahmad, additional, Piccart-Gebhart, Martine, additional, Punie, Kevin, additional, and de Azambuja, Evandro, additional

Published
2023
Full Text
View/download PDF

29. Patterns of care at the end of life: A retrospective study of Italian patients with advanced breast cancer.

Author

Giannubilo, Irene, primary, Battistuzzi, Linda, additional, Blondeaux, Eva, additional, Ruelle, Tommaso, additional, Poggio, Francesca Benedetta, additional, Buzzatti, Giulia, additional, D’Alonzo, Alessia, additional, Rovere, Federica Della, additional, Latocca, Maria Maddalena, additional, Molinelli, Chiara, additional, Razeti, Maria Grazia, additional, Nardin, Simone, additional, Arecco, Luca, additional, Perachino, Marta, additional, Favero, Diletta, additional, Borea, Roberto, additional, Pronzato, Paolo, additional, Mastro, Lucia Del, additional, and Bighin, Claudia, additional

Published
2023
Full Text
View/download PDF

30. Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study

Author

Lambertini, Matteo, Fontana, Valeria, Massarotti, Claudia, Poggio, Francesca, Dellepiane, Chiara, Iacono, Giuseppina, Abate, Annalisa, Miglietta, Loredana, Ferreccio, Chiara, Pescio, Maria Carolina, Conte, Benedetta, Blondeaux, Eva, Bighin, Claudia, D'Alonzo, Alessia, Vaglica, Marina, Zanardi, Elisa, Boccardo, Francesco, Ballestrero, Alberto, Anserini, Paola, and Del Mastro, Lucia

Published
2018
Full Text
View/download PDF

34. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study

Author

Lambertini, Matteo, Ferreira, Arlindo R., Di Meglio, Antonio, Poggio, Francesca, Puglisi, Fabio, Sottotetti, Federico, Montemurro, Filippo, Poletto, Elena, Bernardo, Antonio, Risi, Emanuela, Dellepiane, Chiara, Sini, Valentina, Minuti, Gabriele, Grasso, Donatella, Fancelli, Sara, and Del Mastro, Lucia

Published
2017
Full Text
View/download PDF

36. Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

Author

Lambertini, Matteo Md Phd M., Blondeaux, Eva, Bisagni, Giancarlo, Mura, Silvia, De Placido, Sabino, De Laurentiis, Michelino, Fabi, Alessandra, Rimanti, Anita, Michelotti, Andrea, Mansutti, Mauro, Russo, Antonio, Montemurro, Filippo, Frassoldati, Antonio, Durando, Antonio, Gori, Stefania, Turletti, Anna, Tamberi, Stefano, Urracci, Ylenia, Fregatti, Piero, Razeti, Maria Grazia, Caputo, Roberta, De Angelis, Carmine, Sanna, Valeria, Gasparini, Elisa, Agostinetto, Elisa, de Azambuja, Evandro, Poggio, Francesca, Boni, Luca, Del Mastro, Lucia, Lambertini, Matteo Md Phd M., Blondeaux, Eva, Bisagni, Giancarlo, Mura, Silvia, De Placido, Sabino, De Laurentiis, Michelino, Fabi, Alessandra, Rimanti, Anita, Michelotti, Andrea, Mansutti, Mauro, Russo, Antonio, Montemurro, Filippo, Frassoldati, Antonio, Durando, Antonio, Gori, Stefania, Turletti, Anna, Tamberi, Stefano, Urracci, Ylenia, Fregatti, Piero, Razeti, Maria Grazia, Caputo, Roberta, De Angelis, Carmine, Sanna, Valeria, Gasparini, Elisa, Agostinetto, Elisa, de Azambuja, Evandro, Poggio, Francesca, Boni, Luca, and Del Mastro, Lucia

Abstract

Background: Prior exposure to adjuvant endocrine therapy (ET) and timing to recurrence are crucial factors for first-line treatment choices in patients with hormone receptor-positive/HER2-negative (HR+/HER2−) breast cancer (BC) and in clinical trial eligibility, classifying metastatic HR+/HER2− BC as endocrine sensitive (ES) or primary (1ER)/secondary (2ER) resistant. However, this classification is largely based on expert opinion and no proper evidence exists to date to support its possible prognostic and clinical impact. Methods: This analysis included individual patient-level data from 4 adjuvant phase III randomized trials by the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) study groups. The impact of endocrine resistance/sensitivity classification on overall survival (mOS, defined as time between date of distant relapse and death) was assessed in both univariate and multivariate Cox proportional hazards models. Findings: Between November 1992 and July 2012, 9058 patients were randomized in 4 trials, of whom 6612 had HR+/HER2− BC. Median follow-up was 9.1 years (interquartile range [IQR] 5.6–15.0). In the whole cohort, disease-free survival and OS were 90.4% and 96.6% at 5 years, and 79.1% and 89.4% at 10 years, respectively. The estimated hazard of recurrence raised constantly during the first 15 years from diagnosis, being more pronounced during the first 2 years and less pronounced after year 7. Among the 493 patients with a distant relapse as first disease-free survival event and available date on ET completion, 72 (14.6%), 207 (42.0%) and 214 (43.4%) were classified as having 1ER, 2ER and ES, respectively. Median follow-up from diagnosis of a distant relapse was 3.8 years (IQR 1.6–7.5). Patients with 1ER were significantly more likely to be younger, to have N2/N3 nodal status, grade 3 tumours and to develop visceral metastases. Site of first distant relapse was significantly different between the 3 groups (p = 0.005). In patients with 1ER, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2023

38. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial

Author

Del Mastro, Lucia, primary, Poggio, Francesca, additional, Blondeaux, Eva, additional, De Placido, Sabino, additional, Giuliano, Mario, additional, Forestieri, Valeria, additional, De Laurentiis, Michelino, additional, Gravina, Adriano, additional, Bisagni, Giancarlo, additional, Rimanti, Anita, additional, Turletti, Anna, additional, Nisticò, Cecilia, additional, Vaccaro, Angela, additional, Cognetti, Francesco, additional, Fabi, Alessandra, additional, Gasparro, Simona, additional, Garrone, Ornella, additional, Alicicco, Maria Grazia, additional, Urracci, Ylenia, additional, Mansutti, Mauro, additional, Poletti, Paola, additional, Correale, Pierpaolo, additional, Bighin, Claudia, additional, Puglisi, Fabio, additional, Montemurro, Filippo, additional, Colantuoni, Giuseppe, additional, Lambertini, Matteo, additional, Boni, Luca, additional, Venturini, M, additional, Abate, A, additional, Pastorino, S, additional, Canavese, G, additional, Vecchio, C, additional, Guenzi, M, additional, Lambertini, M, additional, Levaggi, A, additional, Giraudi, S, additional, Accortanzo, V, additional, Floris, C.A., additional, Aitini, E, additional, Fornari, G, additional, Miraglia, S, additional, Buonfanti, G, additional, Cherchi, M.C., additional, Petrelli, F, additional, Vaccaro, A, additional, Magnolfi, E, additional, Contu, A, additional, Labianca, R, additional, Parisi, A, additional, Basurto, C, additional, Cappuzzo, F, additional, Merlano, M, additional, Russo, S, additional, Mansutti, M, additional, Poletto, E, additional, Nardi, M, additional, Grasso, D, additional, Fontana, A, additional, Isa, L, additional, Comandè, M, additional, Cavanna, L, additional, Iacobelli, S, additional, Milani, S, additional, Mustacchi, G, additional, Venturini, S, additional, Scinto, A.F., additional, Sarobba, M.G., additional, Pugliese, P, additional, Bernardo, A, additional, Pavese, I, additional, Coccaro, M, additional, Massidda, B, additional, Ionta, M.T., additional, Nuzzo, A, additional, Laudadio, L, additional, Chiantera, V, additional, Dottori, R, additional, Barduagni, M, additional, Castiglione, F, additional, Ciardiello, F, additional, Tinessa, V, additional, Ficorella, A, additional, Moscetti, L, additional, Vallini, I, additional, Giardina, G, additional, Silva, R, additional, Montedoro, M, additional, Seles, E, additional, Morano, F, additional, Cruciani, G, additional, Adamo, V, additional, Pancotti, A, additional, Palmisani, V, additional, Ruggeri, A, additional, Cammilluzzi, E, additional, Carrozza, F, additional, D'Aprile, M, additional, Brunetti, M, additional, Gallotti, P, additional, Chiesa, E, additional, Testore, F, additional, D'Arco, A, additional, Ferro, A, additional, Jirillo, A, additional, Pezzoli, M, additional, Scambia, G, additional, Iacono, C, additional, Masullo, P, additional, Tomasello, G, additional, Gandini, G, additional, Zoboli, A, additional, Bottero, C, additional, Cazzaniga, M, additional, Genua, G, additional, Palazzo, S, additional, D'Amico, M, additional, and Perrone, D, additional

Published
2022
Full Text
View/download PDF

41. Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy

Author

Lambertini, Matteo, primary, Fielding, Shona, additional, Loibl, Sibylle, additional, Janni, Wolfgang, additional, Clark, Emma, additional, Franzoi, Maria Alice, additional, Fumagalli, Debora, additional, Caballero, Carmela, additional, Arecco, Luca, additional, Salomoni, Sharon, additional, Ponde, Noam F, additional, Poggio, Francesca, additional, Kim, Hee Jeong, additional, Villarreal-Garza, Cynthia, additional, Pagani, Olivia, additional, Paluch-Shimon, Shani, additional, Ballestrero, Alberto, additional, Del Mastro, Lucia, additional, Piccart, Martine, additional, Bines, Jose, additional, Partridge, Ann H, additional, and de Azambuja, Evandro, additional

Published
2022
Full Text
View/download PDF

42. Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate

Author

Poggio, Francesca, Tagliamento, Marco, Ceppi, Marcello, Bruzzone, Marco, Conte, Benedetta, Fregatti, Piero, Punie, Kevin, de Azambuja, Evandro, Del Mastro, Lucia, Lambertini, Matteo, Poggio, Francesca, Tagliamento, Marco, Ceppi, Marcello, Bruzzone, Marco, Conte, Benedetta, Fregatti, Piero, Punie, Kevin, de Azambuja, Evandro, Del Mastro, Lucia, and Lambertini, Matteo

Abstract

SCOPUS: le.j, info:eu-repo/semantics/published

Published
2022

43. Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy

Author

Lambertini, Matteo, Fielding, Shona, Loibl, Sibylle, Janni, Wolfgang, Clark, Emma, Franzoi, Maria Alice, Fumagalli, Debora, Caballero, Carmela, Arecco, Luca, Salomoni, Sharon, Pondé, Noam, Poggio, Francesca, Kim, Hee Jeong, Villarreal-Garza, Cynthia, Pagani, Olivia, Paluch-Shimon, Shani, Ballestrero, Alberto, Del Mastro, Lucia, Piccart-Gebhart, Martine, Bines, Jose, Partridge, Ann A.H., de Azambuja, Evandro, Lambertini, Matteo, Fielding, Shona, Loibl, Sibylle, Janni, Wolfgang, Clark, Emma, Franzoi, Maria Alice, Fumagalli, Debora, Caballero, Carmela, Arecco, Luca, Salomoni, Sharon, Pondé, Noam, Poggio, Francesca, Kim, Hee Jeong, Villarreal-Garza, Cynthia, Pagani, Olivia, Paluch-Shimon, Shani, Ballestrero, Alberto, Del Mastro, Lucia, Piccart-Gebhart, Martine, Bines, Jose, Partridge, Ann A.H., and de Azambuja, Evandro

Abstract

Background: Young age at breast cancer (BC) diagnosis has historically been a rationale for overtreatment. Limited data with short follow-up exist on the prognostic value of age at diagnosis in HER2-positive BC and the benefit of anti-HER2 therapy in young patients. Methods: APHINITY (NCT01358877) is an international, placebo-controlled, double-blind randomized phase III trial in HER2-positive early BC patients investigating the addition of pertuzumab to adjuvant chemotherapy plus trastuzumab. The prognostic and predictive value of age on invasive disease-free survival (IDFS) as continuous and dichotomous variable (aged 40 years or younger and older than 40 years) was assessed. A subpopulation treatment effect pattern plot analysis was conducted to illustrate possible treatment-effect heterogeneity based on age as a continuous factor. Results: Of 4804 included patients, 768 (16.0%) were aged 40 years or younger at enrollment. Median follow-up was 74 (interquartile range = 62-75) months. Young age was not prognostic either as dichotomous (hazard ratio [HR] = 1.06, 95% confidence interval [CI] = 0.84 to 1.33) or continuous (HR = 1.00, 95% CI = 1.00 to 1.01) variable. Lack of prognostic effect of age was observed irrespective of hormone receptor status and treatment arm. No statistically significant interaction was observed between age and pertuzumab effect (Pinteraction = 0.61). Adding pertuzumab improved IDFS for patients in the young (HR = 0.86, 95% CI = 0.56 to 1.32) and older (HR = 0.75, 95% CI = 0.62 to 0.92) cohorts. Similar results were observed irrespective of hormone receptor status. Subpopulation treatment effect pattern plot analysis confirmed the benefit of pertuzumab in 6-year IDFS across age subpopulations. Conclusions: In patients with HER2-positive early BC treated with modern anticancer therapies, young age did not demonstrate either prognostic or predictive value, irrespective of hormone receptor status., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2022

44. Abstract P3-09-03: Single nucletotide polymorphisms of aromatase gene (CYP19A1) and toxicity of adjuvant aromatase inhibitors: A translational, prospective study

Author

Conte, Benedetta, primary, Molinelli, Chiara, additional, Bisagni, Giancarlo, additional, Durando, Antonio, additional, Sanna, Giovanni, additional, Gori, Stefania, additional, Garrone, Ornella, additional, Tamberi, Stefano, additional, De Placido, Sabino, additional, Schettini, Francesco, additional, Pazzola, Antonio, additional, Ponzone, Riccardo, additional, Montemurro, Filippo, additional, Lunardi, Gianluigi, additional, Notaro, Rosario, additional, Turletti, Anna, additional, Bighin, Claudia, additional, Poggio, Francesca, additional, Buzzatti, Giulia, additional, Lambertini, Matteo, additional, Boni, Luca, additional, and Del Mastro, Lucia, additional

Published
2022
Full Text
View/download PDF

45. Abstract P2-13-42: Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial

Author

Lambertini, Matteo, primary, Fielding, Shona, additional, Loibl, Sibylle, additional, Janni, Wolfgang, additional, Clark, Emma, additional, Franzoi, Maria Alice, additional, Fumagalli, Debora, additional, Caballero, Carmela, additional, Arecco, Luca, additional, Salomoni, Sharon, additional, Ponde, Noam F, additional, Poggio, Francesca, additional, Kim, Hee Jeong, additional, Villarreal-Garza, Cynthia, additional, Pagani, Olivia, additional, Paluch-Shimon, Shani, additional, Ballestrero, Alberto, additional, Mastro, Lucia Del, additional, Piccart, Martine, additional, Bines, Jose, additional, Partridge, Ann H., additional, and de Azambuja, Evandro, additional

Published
2022
Full Text
View/download PDF

46. Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial

Author

Conte, Benedetta, primary, Montemurro, Filippo, additional, Levaggi, Alessia, additional, Blondeaux, Eva, additional, Molinelli, Chiara, additional, Cardinali, Barbara, additional, Poggio, Francesca, additional, Buzzatti, Giulia, additional, Bighin, Claudia, additional, Lambertini, Matteo, additional, and Del Mastro, Lucia, additional

Published
2022
Full Text
View/download PDF

47. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis

Author

Poggio, Francesca, primary, Del Mastro, Lucia, additional, Bruzzone, Marco, additional, Ceppi, Marcello, additional, Razeti, Maria Grazia, additional, Fregatti, Piero, additional, Ruelle, Tommaso, additional, Pronzato, Paolo, additional, Massarotti, Claudia, additional, Franzoi, Maria Alice, additional, Lambertini, Matteo, additional, and Tagliamento, Marco, additional

Published
2021
Full Text
View/download PDF

48. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial

Author

Lambertini, Matteo, Boni, Luca, Michelotti, Andrea, Gamucci, Teresa, Scotto, Tiziana, Gori, Stefania, Giordano, Monica, Garrone, Ornella, Levaggi, Alessia, Poggio, Francesca, Giraudi, Sara, Bighin, Claudia, Vecchio, Carlo, Sertoli, Mario Roberto, Pronzato, Paolo, and Del Mastro, Lucia

Published
2015
Full Text
View/download PDF

49. VISTA: A Promising Target for Cancer Immunotherapy?

Author

Tagliamento,Marco, Agostinetto,Elisa, Borea,Roberto, Brandão,Mariana, Poggio,Francesca, Addeo,Alfredo, and Lambertini,Matteo

Subjects
ImmunoTargets and Therapy
Abstract

Marco Tagliamento,1,2 Elisa Agostinetto,3,4 Roberto Borea,2,5 Mariana Brandão,3 Francesca Poggio,6 Alfredo Addeo,7 Matteo Lambertini2,8 1Department of Medical Oncology, Medical Oncology 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 2Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy; 3Institut Jules Bordet and Université Libre de Bruxelles (U.L.B), Brussels, Belgium; 4Medical Oncology and Hematology Unit, IRCCS Humanitas Clinical and Research Center and Humanitas University, Milan, Italy; 5Department of Medical Oncology, Medical Oncology 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 6Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 7Oncology Department, University Hospital of Geneva, Geneva, Switzerland; 8Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, ItalyCorrespondence: Marco TagliamentoDepartment of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, ItalyTel +39 010 5558902Email marco.tagliamento@edu.unige.itAbstract: Agents targeting the B7 family co-inhibitory receptors cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1), or its ligand (PD-L1), have a pivotal role in clinical practice. V-domain Ig suppressor of T-cell activation (VISTA) is a protein highly conserved between species, with a similar amino acid sequence to the B7 family members, characterized by a particularly structural homology to PD-1. It has been counted as an emerging target within the list of novel targetable immune checkpoints in oncology. Physiologically, VISTA exerts a regulatory function on the immune system at several levels, particularly by modulating T cells activation. Its altered activity plays a role in many autoimmune diseases, and its expression has been found to be prognostically implicated in different cancer types in preclinical models. We hereby present the main evidence on the value of VISTA as an immune checkpoint in solid and hematological malignancies. We also review its value as a potential target for cancer immunotherapy, by reporting the results of Phase I and II clinical trials assessing the use of drugs targeting VISTA. The complexity of its pathway, along with some unclear biological aspects concerning its molecular interactions, currently represent a limit to the applicability of VISTA as an effective biomarker for immunotherapy in oncology. A deeper characterization of this immune checkpoint may help defining its value within immune signatures of solid and hematological malignancies, and to design future therapeutic strategies.Keywords: VISTA, immune checkpoint, immunotherapy, cancer, biomarker

Published
2021

50. Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial

Author

Conte, Benedetta, Montemurro, Filippo, Levaggi, Alessia, Blondeaux, Eva, Molinelli, Chiara, Cardinali, Barbara, Poggio, Francesca, Buzzatti, Giulia, Bighin, Claudia, Lambertini, Matteo, and Del Mastro, Lucia

Abstract

Objective: Neoadjuvant chemotherapy has become the preferred treatment in HER2-positive early breast cancer. Several trials investigated the neoadjuvant efficacy of dual HER2 blockade with anthracycline-free chemotherapy, whereas few data are available on single-agent trastuzumab and anthracycline-based regimens, which represent the standard of care in the adjuvant setting. This phase II, single-arm trial assessed anthracycline-based chemotherapy and trastuzumab as neoadjuvant treatment for high-risk HER2-positive breast cancer.Methods: Forty-three patients with stage II–III HER2-positive breast cancer were treated with 4 courses of neoadjuvant 5-fluorouracil 600 mg/m2, epirubicin 90 mg/m2, cyclophosphamide 600 mg/m2(FEC ×4) every 21 days, followed by 12 courses of weekly paclitaxel 80 mg/m2and trastuzumab 2 mg/Kg IV (loading dose 4 mg/kg).Results: Pathologic complete response (pCR) was observed in 22 (51%) of 43 patients. After a median follow-up of 6 years, the 5-year disease-free survival and overall survival were 85.8% (95% confidence interval 75.9%–97%) and 89.6% (80.4%–99.8%), respectively. A temporary decrease in left ventricular ejection fraction was observed in two patients. No cardiac death or congestive heart failure occurred. One patient died due to febrile neutropenia.Conclusions: FEC ×4 followed by paclitaxel and trastuzumab was associated with high pCR rates and favorable long-term outcomes. However, this regimen was associated with relevant hematologic toxicity.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results